Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 7, 2006, Pages 2638-2642

  Rizzoni, Damiano ^a   Paiardi, Silvia ^a   Rodella, Luigi ^a   Porteri, Enzo ^a   De Ciuceis, Carolina ^a   Rezzani, Rita ^a   Boari, Gianluca E M ^a   Zani, Francesca ^a   Miclini, Marco ^a   Tiberio, Guido A M ^a   Giulini, Stefano M ^a   Rosei, Claudia Agabiti ^a   Bianchi, Rossella ^a   Rosei, Enrico Agabiti ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIURETIC AGENT;

ADIPOSE TISSUE; ADULT; ARTERY DISSECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; EXTRACELLULAR MATRIX; FEMALE; GLUTEUS MAXIMUS MUSCLE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MICROCIRCULATION; MUSCLE BIOPSY; MYOGRAPHY; OUTCOME ASSESSMENT; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; TUNICA MEDIA;

ADIPOSE TISSUE; ADULT; ARTERIES; COLLAGEN; COLLAGEN TYPE III; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; TUNICA MEDIA;

ANIMALIA;

EID: 33745791543     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0101     Document Type: Article

References (37)

1. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, Tiberio G, Giulini SM, Monteduro C, Garavelli G, Agabiti Rosei E 1998 Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32:985-992
2. Schiffrin EL 2004 The many targets of aldosterone. Hypertension 43:938-940
3. Hatakeyama H, Miyamori I, Fuijta T, Takeda Y, Takeda R, Yamamoto H 1994 Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269:24316-24320
4. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC1996 Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27:1039-1045
5. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, Giulini SM, Agabiti Rosei E 1996 Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 28:785-790
6. Schiffrin EL, Touyz RM 2004 Form bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 287:H435-H446
7. Neves MF, Virdis A, Schiffrin EL 2003 Resistance artery mechanics and composition in angiotensin II infused rats: effects of aldosterone antagonism. J Hypertens 21:189-198
8. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL 2004 Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43:1252-1257
9. Zannad F, Alla F, Dousset B, Perez A, Pitt B 2000 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 102:2700-2706
10. Iglarz M, Touyz, RM, Viel EC, Amiri F, Schiffirn EL 2004 Involvement of oxidative stress in the profibrotic action of aldosterone. Am J Hypertens 17:597-603
11. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL 2002 Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40:504-510
12. Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mulvany MJ 1987 Evidence for increased media thickness, increased neural amine uptake, and depressed excitation-contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 61:181-186
13. Aalkjaer C, Eiskjaer H, Mulvany MJ, Jespersen B, Kjaer T, Sorensen SS, Pedersen EB 1989 Abnormal structure and function of isolated subcutaneous resistance vessels from essential hypertensive patients despite antihypertensive treatment. J Hypertens 7:305-310
14. Mulvany MJ, Hansen PK, Aalkjaer C 1978 Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res 43:854-864
15. Mulvany MJ, Aalkjaer C 1990 Structure and function of small arteries. Physiol Rev 70:921-971
16. Rizzoni D, Porteri E, Boari GEM, De Ciuceis C, Sleiman I, Muiesan ML, Castellano M, Miclini M, Agabiti-Rosei E 2003 Prognostic significance of small artery structure in hypertension. Circulation 108:2230-2235
17. Sund S, Grimm P, Reisaeter AV, Hovig T 2004 Computerized image analysis vs. semiquantitative scoring in evaluation of kidney allograft fibrosis and prognosis. Nephrol Dial Transplant 19:2838-2845
18. Vranes D, Cooper ME, Dilley RJ 1999 Cellular mechanisms of diabetic vascular hypertrophy. Microvasc Res 57:8-18
19. Rizzoni D, Porteri E, De Ciuceis C, Sleiman I, Rodella L, Rezzani R, Paiardi S, Bianchi R, Ruggeri G, Boari GEM, Muiesan ML, Salvetti M, Zani F, Miclini M, Agabiti Rosei E 2005 Effects of treatment with candesartan or enalapril on subcutaneous small resistance artery structure in hypertensive patients with NIDDM. Hypertension 45(Pt 2):659-665
20. Weber KT 2000 Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15:264-272
21. Tunion J, Ruiz-Ortega M, Egido J 2000 Regulation of matrix proteins and impact of vascular structure. Curr Hypertens Rep 2:106-113
22. Integan HD, Schiffrin EL 001 Vascular remodeling in hypertension: role of apoptosis, inflammation and fibrosis. Hypertension 38(Pt 2):581-587
23. Integan HD, Schiffrin EL 2000 Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312-318
24. Integan HD, Deng LY, Li JS, Schiffrin EL 1999 Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 33:569-574
25. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, Girelli A, Rodella L, Bianchi R, Sleiman I, Agabiti Rosei E 2001 Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non insulin dependent diabetes mellitus. Circulation 103:1238-1244
26. 1 receptor antagonist losartan in essential hypertension. J Renin Angiotens Syst 1:40-45
27. Thybo NK, Mulvany MJ, Jastrup B, Nilesen H, Aalkjaer C 1996 Some pharmacological and elastic characteristics of isolated subcutaneous small arteries from patients with essential hypertension. J Hypertens 14:993-998
28. Rizzoni D, Porteri E, Guelfi D, Piccoli A, Castellano M, Pasini G, Muiesan ML, Mulvany MJ, Agabiti Rosei E 2000 Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 35:931-935
29. Porteri E, Rizzoni D, Mulvany MJ, De Ciuceis C, Sleiman I, Boari GEM, Castellano M, Muiesan ML, Zani F, Agabiti Rosei E 2003 Adrenergic mechanisms and remodelling of subcutaneous small resistance arteries. J Hypertens 21:2345-2352
30. Lijnen P, Petrov V 2000 Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 32:865-879
31. Stier CT, Rocha R, Chander PN 2005 Effect of aldosterone and MR blockade on the brain and the kidney. Heart Fail Rev 10:53-62
32. Stier Jr CT, Chander PN, Rocha R 2002 Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10:97-107
33. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL 2003 Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42:49-55
34. Park JB, Schiffrin EL 2002 Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 15:164-169
35. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ 2002 Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metabol 87:448-452
36. Suga SI, Phillips MI, Ray PE, Raleigh JA, Vio CP, Kim YG, Mazzali M, Gordon KL, Hughes J, Johnson RJ 2001 Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. Am J Physiol Renal Physiol 281:F620-F629
37. Rizzoni D, Porteri E, De Ciuceis C, Sleiman I, Rodella L, Rezzani R, Paiardi S, Bianchi R, Ruggeri G, Boari GE, Muiesan ML, Salvetti M, Zani F, Miclini M, Agabiti Rosei 2005 Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with non insulindependent diabetes mellitus. Hypertension 45:659-665